Purpose: Given the emerging evidence for differential responses to new targeted therapies and the identification of molecular differences between specific subtypes of non-small cell lung carcinoma (NSCLC), there is an increased need for greater accuracy in subtyping NSCLC. In a substantial proportion of cases, standard morphology cannot specifically subtype the tumor, resulting in a final diagnosis of NSCLC-not otherwise specified. In this study, we added newly proposed markers (napsin A, desmocollin-3) to conventional markers (p63, thyroid transcription factor-1 [TTF-1], cytokeratin 5/6 [CK5/6], high molecular weight cytokeratin [HMWCK], cytokeratin 7 [CK7]) and evaluated for the minimal panel of immunohistochemical markers required for subtyping poorly differentiated (PD) NSCLC. Materials and Methods: Resection specimens of 110 adenocarcinomas (ADCs) and 171 squamous cell carcinomas (SCCs) were collected and tissue microarrays were constructed to simulate small biopsy conditions. All specimens were stained with TTF-1, napsin A, CK7, p63, CK5/6, HMWCK, desmocollin-3 and mucicarmine. Results: For 32 PD ADC, a combination of TTF-1 and napsin A increased sensitivity (81%). With regard to the 29 PD SCC, a combination of desmocollin-3 and p63 did not substantially increase diagnostic performance. Logistic regression analysis identified napsin A, p63 and TTF-1 as the optimal panel to separate PD ADC and PD SCC. Mucin stains for PD NSCLC increased accuracy rate (88%) for diagnosis of PD ADC. Conclusion: We recommend a minimal panel of immunohistochemical and histochemical markers to include TTF-1, p63, napsin A and one of mucin stains for tumor subtyping of PD NSCLC in a small biopsy sample. (J Lung Cancer 2012;11(1):21 32)
INTRODUCTION
Lung cancer is the most common cause of cancer-related mortality in the world today. Primary lung cancer has been classified into 2 clinically relevant groups: small cell lung carcinoma (SCLC) and non-small cell lung carcinoma (NSCLC).
This distinction was clinically useful as available treatment strategies differed significantly between these 2 groups. More recently, the identification of molecular differences between specific subtypes of NSCLC and the emerging evidence for differential responses to new targeted therapies has necessitated greater accuracy in the subtyping of NSCLC. Adenocarcinoma (ADC) and squamous cell carcinoma (SCC) are the 2 major subtypes of NSCLC. Recent clinical trials for NSCLC revealed that some chemotherapeutic regimens (e.g., pemetrexed) were apparently more effective for non-SCC than for SCC (1) , while other agents (e.g., bevacizumab) were of limited use for SCC because of fatal pulmonary hemorrhage risks (2) . Moreover, the ADC subtype is more predictive of a better response to epidermal growth factor receptor inhibitors, especially in Asian women who have never smoked (2) . Consequently, accurate (29) 29 (17) 61 (22) Values are presented as number (%). ADC: adenocarcinoma, SCC: squamous cell carcinoma.
histologic typing of NSCLC is essential when formulating treatment therapies (3).
Many NSCLC are heterogeneous and show areas of undifferentiated tumor that lack the light-microscopic features of differentiation visible in other parts of the lesion. The combination of a small diagnostic sample size and tumor heterogeneity results in a lack of consistency and accuracy in subtyping NSCLCs (4, 5) . Morphologic separation of poorly differentiated (PD) ADC from PD SCC can be difficult, with low interobserver agreement even among experienced pulmonary pathologists (6) . Some studies have found that this diagnosis accounts for up to 25% of NSCLC diagnoses in small biopsy and 45% of cytology samples (7) . When PD NSCLC is present in small biopsy sample, a diagnosis of non-small cell lung carcinoma-not otherwise specified (NSCLC-NOS) is recommended (8) (9) (10) . However, this has led to the used of the NSCLC-NOS diagnosis in more than 30% of histologic and close to 40% of cytologic samples (11) . Immunohistochemistry (IHC) can allow tumor subtypes to be inferred when histologic morphology is nonspecific. While none of the markers to date have 100% sensitivity or specificity, most studies have agreed on the inclusion of thyroid transcription factor-1 (TTF-1) as an ADC marker and p63 as an SCC marker. Other markers, such as cytokeratin 5/6 (CK5/6), cytokeratin 7 (CK7), desmocollin-3, high molecular weight cytokeratin (HMWCK), and napsin A, may also contribute to tumor subtyping (12) (13) (14) (15) (16) (17) (18) (19) .
In this study, we investigated 4 SCC markers (CK5/6, desmocollin-3, HMWCK, and p63) and 3 ADC markers (CK7, napsin A, and TTF-1) using a tissue microarray (TMA) format sampled from resection specimens diagnosed as SCC and ADC to simulate small biopsy conditions. We evaluated the ability of these IHC markers and mucin staining to predict the most likely NSCLC subtype. 
MATERIALS AND METHODS

1) Patients and specimens
2) Tumor tissue and TMAs
The paraffin embedded tissues were sampled from archived conventional tissue blocks. Three areas of tumor were chosen 
3) IHC and histochemistry
Primary antibodies, sources, and dilutions are listed in Table   2 . Antibodies were applied to 4-μm-thick TMA sections using 
5) Data analysis
The significance of relationships between tumor differen- 
RESULTS
1) Immunohistochemical findings by tumor differentiation
Immunohistochemical findings according to tumor differentiation are present in Table 3 . TTF-1 was positive in 75 of 110 (68%) ADCs sampled and in none of the SCCs. Desmocollin-3
was positive in 156 of 171 (91%) SCCs and in none of the ADCs. Desmocollin-3 and p63 had significantly decreased immunoreactivity in PD SCC (59% and 86%). However, p63
immunoreactivity was the highest (86%) among the SCC markers in PD SCC. CK7 immunoreactivity expression was significantly increased in PD SCC (28%).
2) Sensitivity, specificity, PPV, NPV, and AUC on ROC of one marker
The sensitivities, specificities, PPV, NPV, and AUC on ROC of the markers for ADC and SCC are presented in Table 4 .
For ADC, the single most sensitive marker and best negative predictor was CK7 (sensitivity, 95%; NPV, 96%), and the most specific and best positive predictor was TTF-1 (specificity, 100%; PPV, 100%). Napsin A was specific (98%) for ADC and the 95% CI for specificity and PPV overlapped with those of TTF-1. For SCC, p63 is the most sensitive marker and best negative predictor (sensitivity, 96%; NPV, 93%). Desmocollin-3 was the most specific and best positive predictor (specificity, 100%, PPV, 100%). Among the PD, the same results were found. TTF-1 and desmocollin-3 were mutually expressed exclusively in ADCs and SCCs, respectively. CK7
was both highly sensitive (95%) and specific (91%) for ADC.
However, CK7 was less specific (72%) in PD ADCs. Desmocollin-3 was both highly sensitive (91%) and specific (100%).
However, desmocollin-3 was not sensitive (59%) in PD SCCs.
AUC on ROC represents an optimal summary statistic for comparing the sensitivity and specificity of the markers. For 110 ADCs including all histologic grades, CK7 (0.97) had the greatest AUC, followed by napsin A (0.90), and TTF-1 (0.84).
For 171 SCCs including all histologic grades, p63 (0.97) had 
3) Sensitivity, specificity, PPV, NPV, and AUC on ROC of individual and combined markers in 32 PD ADCs and 29 PD SCCs
The sensitivities, specificities, PPV, NPV, and AUC on ROC of combined markers for PD ADC and PD SCC are presented in Tables 5 and 6 , respectively. These findings indicate that the best single marker for PD ADC and PD SCC, based on sensitivity, specificity, and AUC on ROC, would be napsin A and p63, respectively. A combination of TTF-1 and napsin A increased the sensitivity (81%) and AUC on ROC (0.89) for PD ADC. However, desmocollin-3 and CK5/6 combined with p63 were not superior to p63 alone for PD SCC. 
4) Immunohistochemical co-expression patterns of 32 PD
ADCs and 29 PD SCCs
Immunohistochemical coexpression patterns for diagnosis of 32 PD ADCs and 29 PD SCCs were provided in Table 7 . Since the reactivity for individual makers did not discriminate between ADC and SCC, we examined whether there was an overlap in expression for a various combination of markers.
Eight Napsin positive cases were negative for TTF-1. Six NSCLC-NOS were 4 ADCs and 2 SCCs in reference diagnosis (diagnosis of resection specimen). 
5) Panels of immunohistochemical and histochemical markers, and AUC on ROC using logistic regression analysis for subtyping 61 PD NSCLCs
Logistic regression analysis (Table 8) 
DISCUSSION AND CONCLUSION
Histopathologic classification of lung carcinoma is important, as a prognostic factor and in the evaluation for potential treatment modalities. Although the reproducibility rate of the pathologic diagnoses, based on routine light microscopic features is satisfactory for distinguishing between SCLC from NSCLC and for detection of glandular vs. squamous differentiation in well to moderately differentiated ADC and SCC, it is less than satisfactory for identifying PD SCC from PD ADC, especially in small biopsy tissues obtained by bronchoscopy or gun biopsy. In addition, the distinction of PD NSCLC can be difficult in small tissue biopsies, due to a variety of factors, such as crush artifact, necrosis, less than optimal fixation, and the overlapping cytologic characteristics of these tumors. According to existing evidence, about 75% of NSCLCs in biopsies need only routine H&E staining to be identified as ADC or SCC (7, 22) . In our study, well to moderately-differentiated NSCLC (H&E stain-diagnosable) was 78%.
TTF-1 is a tissue-specific transcription factor that mediates cell determination and differentiation in lung, thyroid, and brain. It is normally expressed in alveolar pneumocytes, Clara cells, ciliated respiratory epithelial cells, and basal cells of the lung (23) . TTF-1 positivity has been reported in 5 to 21% of SCCs (24) (25) (26) . However, based on our study and that of others, TTF-1 does not stain pulmonary SCC (27) (28) (29) . Napsin A, an aspartic proteinase involved in the maturation of surfactant protein B, has been favored as a new diagnostic marker for pulmonary ADC (12, 30) . As reported, it is normally expressed by type II pneumocytes, alveolar macrophages, and the epithelium of proximal and convoluted renal tubules (31) . In a recent study, the sensitivities of TTF-1 and napsin A for pulmonary ADC were 73% and 83%, respectively (32) . From our data, the sensitivities of TTF-1 and napsin A were 56%
and 69% in PD ADC, respectively. Despite these lower figures in PD ADC, the sensitivity of napsin A was a higher than that of TTF-1. Eight Napsin positive cases were negative for TTF-1. Thus, we excluded the desmocollin-3 from the immunohistochemical panel for subtyping PD NSCLC in our study.
The reported sensitivity of CK5/6 for pulmonary SCC ranges from 61% to 93% (16, 17, 22, 29, (34) (35) (36) . Kargi et al. (16) found that p63 and CK5/6 differentially stained easily recognizable ADC and SCC with 89% specificity and 79% sensitivity.
Kaufmann et al also found that combination of p63 and CK5/6 was superior to either marker alone in H&E stain-diagnosable, but the sensitivity diminished to 73% in PD SCC. Furthermore, they reported that if a positive result required ＞50% of cells to be stained, specificity rose to 99%, while sensitivity fell to 66% (34) . In our study, CK5/6 had a lower sensitivity (76%) than p63 (97%) in PD SCC. The specificity was 88%, which was similar to p63. A combination of the 2 markers (100% sensitivity) slightly increased the diagnostic performance compared to p63 alone (97% sensitivity). However, the specificity decreased from 88% to 78%. In AUC on ROC analysis, CK5/6, p63, and the combination of the 2 markers were 0.82, 0.95, and 0.89, respectively. CK5/6 alone or combination was statistically superior to desmocollin-3 (0.79 AUC on ROC), but not to p63
which is in accordance with the results of a previous study (22, 36) . In our study, CK7 was both highly sensitive (95%) and specific (91%) for all grades of 110 ADCs. Even though, diffuse strong immunoreactivity was considered positive, CK7
was less specific (72%) in PD ADC. HMWCK for SCC was highly sensitive (95%) but too nonspecific (62%) to be diagnostically useful. In practice, ancillary immunohistoche- and SCC markers (p63 and desmocollin-3) were diagnosed as NSCLC-NOS (10%, 6/61). Of the 6 NSCLC-NOS specimens, 4 were ADC and 2 were SCC in reference diagnosis (resection specimen).
In conclusion, we recommend a minimal panel of immunohistochemical and histochemical markers to include TTF-1, p63
napsin A and one of mucin stains for tumor subtyping of PD NSCLC in a small biopsy sample. This recommended panel reached an accuracy of 90% for subtyping PD NSCLC.
